⌘+K

Pulse Explore Communities Researchers Journals

Browser extensionInstagram

Home Communities Explore

October 1, 2012Expert Review of VaccinesOpen Access

Vaccinating against Japanese encephalitis virus: what have we learned from recent clinical trials?

Katrin Dubischar-Kastner Niranjan Kanesa-thasan

View Full Paper

Ask AI

Bookmark

Share

Ask about this paper

Answers are grounded in this paper and cite their sources.

Ask your own question…

Abstract

The burden of Japanese encephalitis (JE) remains substantial despite increasing JE vaccine coverage [1]. Mouse-brain-derived (MB) JE vaccines are being replaced by second-generation JE vaccines pro...

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Dubischar-Kastner et al. (2012) studied this question.

synapsesocial.com/papers/6a7def88603f5e16dd33aea9 https://doi.org/10.1586/erv.12.100

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 10 related papers. Consider them for comparative context:

1Estimated global incidence of Japanese encephalitis:systematic_review · 2011 · 1,004 citations
2New Japanese encephalitis vaccines: alternatives to production in mouse brainReview · 2011 · 132 citations
3IMOJEV<sup>®</sup>: a Yellow fever virus-based novel Japanese encephalitis vaccineLate-Phase Clinical Trial · 2010 · 70 citations
4Safety and Immunogenicity of a Single Administration of Live-attenuated Japanese Encephalitis Vaccine in Previously Primed 2- to 5-year-olds and Naive 12- to 24-month-oldsOriginal Research · 2010 · 76 citations
5A Single Dose of Vero Cell-Derived Japanese Encephalitis (JE) Vaccine (Ixiaro) Effectively Boosts Immunity in Travelers Primed With Mouse Brain-Derived JE Vaccinescohort · 2012 · 39 citations
6Respiratory syncytial virus (RSV) vaccine recommendations for adults: a review of available global, regional, and country level recommendationsExpert Review of Vaccines · 2026
7Association of the publicly funded two-dose varicella vaccine policy with varicella incidence in Shanghai: an interrupted time series studyExpert Review of Vaccines · 2026
8Effectiveness and implementation of electronic decision support for adult vaccination in primary care: a mixed-methods quasi-experimental evaluationExpert Review of Vaccines · 2026
9Modeling the cost-effectiveness of NVX-CoV2705 and the public health impact of vaccination for the prevention of seasonal COVID-19 in the USExpert Review of Vaccines · 2026
10Progress toward HIV-1 subtype C vaccines: understanding antiviral immune mechanisms and viral adaptationExpert Review of Vaccines · 2026

More from Expert Review of Vaccines

More from Vienna Biocenter

More from Tris Pharma (United States)

More from Novartis Foundation

More from Intercell (Austria)